Orion comments on new challenge by Sun Pharmaceutical Industries Ltd., India, of Orion's U.S. Patent covering Stalevo in the US

Company states the realisation of generic competition is neither certain nor imminent

04-Jan-2008 - Orion Corporation has been informed that Sun Pharmaceutical Industries Ltd., India (Sun), has amended its Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking authorisation to produce and market generic versions of Stalevo® tablets (25/100/200 and ...

Orion sues Sun Pharmaceuticals in the U.S. to enforce a patent for Stalevo

Company states the realisation of generic competition is neither certain nor imminent

15-Nov-2007 - Orion Corporation has filed a patent infringement lawsuit in the United States to enforce its formulation patent, U.S. Patent No. 6,500,867, against Sun Pharmaceutical Industries Inc. and Sun Pharmaceutical Industries Limited, who seek to market generic versions of Stalevo® tablets (25/100/200 ...

Orion sues generic drug companies in the U.S. to enforce patents for entacapone

17-Sep-2007 - Orion Corporation has filed a patent infringement lawsuit in the United States to enforce U.S. Patent No. 5,446,194 and U.S. Patent No. 5,135,950 against generic drug companies Wockhardt USA, Inc. and Wockhardt Limited, who seek to market generic entacapone (200 mg tablets) in the United States. ...

New President and CEO for Orion Corporation as of 1 January 2008

13-Sep-2007 - President and CEO of Orion Corporation Jukka Viinanen will retire on 29 February 2008 as agreed between him and Orion Corporation. As of 1 January 2008 he will step aside from the position of President and CEO to act as a Senior Advisor to the Board of Directors of Orion Corporation until his ...